STI 6643
Alternative Names: STI-6643Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Sorrento Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 18 Nov 2021 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT04900519)
- 01 Jun 2021 Sorrento Therapeutics plans a phase I trial for Solid Tumor(Second line therapy or greater; late stage disease) in August 2021 (NCT04900519),